Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 5:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 6,423 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin-to-skin Clear all
Not listed Phase 2 Interventional

Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris

NCT00098358
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Zileuton
Drug
Lead sponsor
Critical Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
12
States / cities
San Diego, California • Newnan, Georgia • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2007 · Synced Oct 11, 2026, 5:37 AM EDT
Completed Phase 1Phase 2 Interventional

Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver

NCT00041808
View directory record Official record
Conditions
Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Breast Neoplasms, Melanoma, Sarcoma, Gastrointestinal Neoplasms, Lung Neoplasms, Liver Neoplasms, Cholangiocarcinoma
Interventions
MTC-DOX for Injection, Chemotherapy
Drug · Procedure
Lead sponsor
FeRx
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
3
States / cities
San Diego, California • San Francisco, California • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 11, 2026, 5:37 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma

NCT01339663
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
cyclophosphamide, aldesleukin, autologous tumor cell vaccine, laboratory biomarker analysis, immunologic technique, immunohistochemistry staining method, polymerase chain reaction, therapeutic autologous lymphocytes
Drug · Biological · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 11, 2026, 5:37 AM EDT
Terminated Phase 2 Interventional Results available

A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)

NCT00183963
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Tamoxifen, Fulvestrant
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 11, 2026, 5:37 AM EDT
Completed Phase 2 Interventional

Methimazole to Treat Polymyositis and Dermatomyositis

NCT00001421
View directory record Official record
Conditions
Dermatomyositis, Polymyositis
Interventions
methimazole
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 11, 2026, 5:37 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis

NCT03831438
View directory record Official record
Conditions
Scleroderma, Diffuse
Interventions
AVID200
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 11, 2026, 5:37 AM EDT
Terminated Phase 3 Interventional Results available

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

NCT01242514
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Fostamatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,917 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
116
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 113 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2014 · Synced Oct 11, 2026, 5:37 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer

NCT00003352
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, Taxotere, Adriamycin
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
152
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 120 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Oct 11, 2026, 5:37 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome

NCT04251026
View directory record Official record
Conditions
Mucopolysaccharidosis II
Interventions
tividenofusp alfa
Drug
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
Up to 18 Years · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
4
States / cities
Oakland, California • Chicago, Illinois • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 11, 2026, 5:37 AM EDT
Withdrawn No phase listed Observational

A Pilot Study to Explore the Role of Gut Flora in Rheumatoid Arthritis

NCT04210817
View directory record Official record
Conditions
Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis
Interventions
No Intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 11, 2026, 5:37 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

NCT02804763
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Placebo, Dapirolizumab pegol (DZP)
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
25
States / cities
Birmingham, Alabama • El Cajon, California • Huntington Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 11, 2026, 5:37 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study

NCT01711814
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
peficitinib
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
20
States / cities
Birmingham, Alabama • La Jolla, California • Palm Desert, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 11, 2026, 5:37 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy

NCT02527343
View directory record Official record
Conditions
Familial Partial Lipodystrophy
Interventions
volanesorsen, Placebo
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 11, 2026, 5:37 AM EDT
Completed Phase 2 Interventional Results available

NOLAN: Naproxen or Loratadine and Neulasta

NCT01712009
View directory record Official record
Conditions
Bone Pain in Stage I - III Breast Cancer
Interventions
Naproxen, Loratadine, Pegfilgrastim, Chemotherapy
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
83
States / cities
Muscle Shoals, Alabama • Anaheim, California • Fullerton, California + 78 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Oct 11, 2026, 5:37 AM EDT
Completed Phase 2 Interventional Results available

Anakinra as a Treatment for Hydradenitis Suppurativa

NCT01516749
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
anakinra
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 11, 2026, 5:37 AM EDT
Completed No phase listed Observational

Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment

NCT02695121
View directory record Official record
Conditions
Breast Cancer, Bladder Cancer
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
2,133,575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Wilmington, Delaware • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 11, 2026, 5:37 AM EDT
Withdrawn No phase listed Observational

A Pilot Study to Explore the Role of Gut Flora in Eczema

NCT04214548
View directory record Official record
Conditions
Eczema
Interventions
No Intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 11, 2026, 5:37 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis

NCT00195689
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Human anti-TNF monoclonal antibody/adalimumab
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 29, 2007 · Synced Oct 11, 2026, 5:37 AM EDT
Recruiting Not applicable Interventional

Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)

NCT06445738
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female
Interventions
Arm A: Radiotherapy Omission, Arm B: Standard Treatment
Radiation · Other
Lead sponsor
Breast Cancer Trials, Australia and New Zealand
Other
Eligibility
50 Years and older · Female only
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2039
U.S. locations
2
States / cities
San Francisco, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 11, 2026, 5:37 AM EDT
Completed Phase 1 Interventional Results available

A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers

NCT02154425
View directory record Official record
Conditions
Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis
Interventions
Breast milk sampling, Certolizumab Pegol
Procedure · Biological
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 11, 2026, 5:37 AM EDT
Not yet recruiting Not applicable Interventional

Use of Fish Skin Graft (FSG) to Improve Wound Healing and Expedite Discharge at a County Safety-net Hospital

NCT06910189
View directory record Official record
Conditions
Surgical Wound
Interventions
Fish Skin Graft (FSG), Wound Vacuum-Assisted Closure (VAC)
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 11, 2026, 5:37 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

NCT02941926
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib, Letrozole, Goserelin, Leuprolide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
71
States / cities
Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 11, 2026, 5:37 AM EDT
Terminated Phase 2 Interventional Results available

Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II

NCT05047185
View directory record Official record
Conditions
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
Interventions
Deucrictibant low dose, Deucrictibant high dose, Placebo
Drug
Lead sponsor
Pharvaris Netherlands B.V.
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 11, 2026, 5:37 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

NCT03717415
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumor
Interventions
Rebastinib, Carboplatin
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
San Francisco, California • Santa Monica, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 11, 2026, 5:37 AM EDT